Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

By sjmartinez • August 13, 2024

Narkhede M, Tomassetti S, Iqbal M, Tin A, Rivero-Hinojosa S, George GV, Widden H, Benrud R, Malhotra M, Rodriguez A, Liu MC. Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma. Front Oncol. 2024 Jul 29;14:1407003. doi: 10.3389/fonc.2024.1407003. PMID: 39135998; PMCID: PMC11317400.

Tags: circulating tumor DNA, Harbor UCLA, Hematology/Oncology, molecular residual disease, Next generation sequencing, Publications, surveillance, treatment response monitoring

Facilitators and challenges in the implementation of the Care Ecosystem at six clinical sites in the United States: A qualitative study

Sideman AB, Merrilees J, Dulaney S, Allawala M, Barclay M, Rosenbloom M, Hanson LR, Ward KT, Hess M, Olney NT, Lum HD, Sawyer RJ, Possin[...]

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani[...]